Hypolipidemic Therapy and HDL
DOI:
https://doi.org/10.2015/hc.v5i1%20Sup.372Abstract
Statins significantly reduce cardiovascular events by reducing low-density-lipoprotein cholesterol (LDL-C). However, despite achieving the LDL goals, a substantial residual risk remains. It appears that low levels of high-density lipoprotein cholesterol (HDL-C) constitute another independent risk factor for coronary artery disease (CAD). Therefore, raising HDL levels appears an attractive target to further reduce the cardiovascular risk. However, classical HDL-reducing drugs (nicotinic acid derivatives, fibrates) are not well tolerated and newer agents (torcetrapid), which seemed effective in doing that, had to be withdrawn due to increased mortality. Nevertheless, due to the importance of HDL in influencing the cardiovascular risk, efforts in developing safer drugs are continuing. Such pharmacological developments, as well as the nonpharmacological approaches to increase HDL, and other HDL-targeted therapies are discussed in this overview.Downloads
Issue
Section
License
Authors who publish with this journal agree to the following terms:a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
